CLARUS THERAPEUTICS
Clarus Therapeutics is a biopharmaceutical company that develops androgen-based medicines for men and women. It offers OriTex, a proprietary oral testosterone product for use in men with low testosterone levels.
CLARUS THERAPEUTICS
Industry:
Biotechnology Health Care Life Science Therapeutics
Founded:
2003-01-01
Address:
Northbrook, Illinois, United States
Country:
United States
Website Url:
http://www.clarustherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
847-562-4300
Email Addresses:
[email protected]
Total Funding:
122 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins
Similar Organizations
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
H.I.G. Capital
H.I.G. Capital investment in Post-IPO Equity - Clarus Therapeutics
C-Bridge Capital
C-Bridge Capital investment in Venture Round - Clarus Therapeutics
Armentum Partners
Armentum Partners investment in Debt Financing - Clarus Therapeutics
H.I.G. Capital
H.I.G. Capital investment in Series C - Clarus Therapeutics
Thomas, McNerney & Partners
Thomas, McNerney & Partners investment in Series C - Clarus Therapeutics
Thomas, McNerney & Partners
Thomas, McNerney & Partners investment in Series B - Clarus Therapeutics
Thomas, McNerney & Partners
Thomas, McNerney & Partners investment in Series A - Clarus Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-18 | Clarus Therapeutics cutting staff, replacing CFO |
| 2022-01-18 | Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer |
Official Site Inspections
http://www.clarustherapeutics.com
- Host name: 172.67.170.194
- IP address: 172.67.170.194
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Clarus Therapeutics"
Clarus Therapeutics - Crunchbase Company Profile & Funding
Organization. Clarus Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email …See details»
Clarus Therapeutics - LinkedIn
Clarus Therapeutics | 1,586 followers on LinkedIn. Driven by a mission to help men overcome the health-eroding symptoms of hypogonadism | Clarus Therapeutics, Inc. is a men's specialty ...See details»
Clarus Therapeutics Closes Transaction With Blue Water, Debuts as …
Sep 9, 2021 Business combination with Blue Water Acquisition Corp., a special purpose acquisition company, completed on September 9, 2021 Combined company to be renamed …See details»
Clarus Therapeutics Company Profile 2024: Valuation, Funding ...
Clarus Therapeutics General Information Description. Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for …See details»
Clarus Therapeutics - Overview, News & Similar companies
Oct 27, 2022 View Clarus Therapeutics (www.clarustherapeutics.com) location in Illinois, United States , revenue, industry and description. Find related and similar companies as well as …See details»
Blue Water Acquisition Announces Merger Agreement with Clarus ...
Apr 27, 2021 For more information, visit www.clarustherapeutics.com and www.jatenzo.com . About Blue Water Acquisition Corp. Blue Water Acquisition is a special purpose acquisition …See details»
Clarus Therapeutics Holdings, Inc. Announces Plan for
Sep 6, 2022 Clarus Therapeutics’ first commercial product is JATENZO (testosterone undecanoate capsules; C-III). For more information, visit www.clarustherapeutics.com and …See details»
Clarus Therapeutics and McGill University Announce Licensing …
Oct 11, 2023 Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential …See details»
Clarus Therapeutics Announces Closing of Approximately $15 …
Dec 7, 2021 Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clarus …See details»
Clarus Therapeutics Holdings, Inc. Announces Completion of …
Oct 18, 2022 Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- …See details»
Clarus Therapeutics Closes Transaction With Blue Water,
Sep 9, 2021 [email protected]. Blue Water Contact: Joseph Hernandez Chief Executive Officer 15 E. Putnam Avenue, Suite 363 Greenwich, CT 06830 (646) 303-0737. …See details»
Clarus Therapeutics to Report Fourth Quarter and Full Year
Mar 29, 2022 [email protected] (847) 562-4300 x 206. Tags Clarus ...See details»
Clarus Therapeutics: Advancing Androgen Replacement And …
Dec 1, 2021 Summary. Clarus Therapeutics is a commercial stage pharmaceutical company advancing androgen replacement and metabolic therapies. The Company’s lead product …See details»
Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term …
Sep 6, 2022 Bidding process and auction for JATENZO (testosterone undecanoate capsules; C-III) projected to conclude late October 2022NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE …See details»
Clarus Therapeutics Reports Fourth Quarter and Full Year
Mar 30, 2022 The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 5454819. A live webcast and replay of …See details»
Clarus Therapeutics to Report First Quarter 2022 Financial and ...
Clarus will host a conference call on Monday, May 16, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for …See details»
Clarus Therapeutics Announces Closing of Approximately $15
Dec 7, 2021 Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clarus...See details»
Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 …
Clarus Therapeutics Holdings, Inc. 2021 net revenue increased 119% year-over-year to $14.0 million. Fourth quarter 2021 net revenue increased 88% year-over-year to $4.6 millionSee details»
Clarus Therapeutics Reports First Quarter 2022 Financial and …
May 16, 2022 First quarter 2022 net revenue increased 72% year-over-year to $4.0 million First quarter 2022 total prescription growth for JATENZO® increased 12% sequentially and …See details»
Clarus Therapeutics Announces $15 Million Private Placement
Mar 12, 2021 Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Clarus...See details»